ICD Therapy Confers No Survival Advantage in a Global LVAD Population: Insights from the Trans-Atlantic Registry on VAD and Transplant (TRAViATA)

O. Braun,M. Brambatti,P. Shah,M. Cipriani, J. Veenis, Q. Bui,K. Hong,C. Van de Heyning,E. Perna, P. Timmermans,M. Cikes, G. Gjesdal, C. Partida, L. Potena,M. Masetti,A. Loforte,N. Jakus,J. Nilsson,D. De Bock, J. Minto, J. Brugts, C. Sterken,K. Van den Bossche, F. Rega, R. Sing,C. Russo,V. Pretorius,L. Klein,M. Frigerio,E. Adler,E. Ammirati

JOURNAL OF HEART AND LUNG TRANSPLANTATION（2020）

Cited 0|Views95

No score

Abstract

In this retrospective study of LVAD patients from the EU and US ICD therapy conferred no survival advantage irrespective of geographic location. A prospective, randomized, trial of LVAD patients who have an existing ICD randomized to tachyarrhythmia therapy discontinuation is needed to validate these findings.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined